Novo Nordisk is partnering with artificial intelligence firm OpenAI to accelerate drug discovery and development. The collaboration will integrate OpenAI’s AI capabilities throughout the Danish drugmaker’s operations.
The partnership aims to enhance workflows from lab-based research to manufacturing and commercial operations. Novo Nordisk intends to leverage AI to analyze complex data and identify promising new drug candidates.
This move comes as Novo Nordisk seeks to regain ground in the competitive weight-loss drug market. The company will embed intelligent agents to assist employees in data analysis and overall drug development processes.